Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
AstraZeneca PLC (NASDAQ:AZN) announced Monday that its investigational drug baxdrostat met both the primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with uncontrolled or treatment-resistant hypertension. The company reported that baxdrostat, at doses of 2mg and 1mg, showed a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo after 12 weeks of treatment.
The BaxHTN trial was a multicenter, randomized, double-blind, placebo-controlled study involving 796 patients. Participants received baxdrostat or placebo in addition to standard care. The primary efficacy endpoint was the difference in mean change from baseline in seated systolic blood pressure at week 12. Secondary endpoints included outcomes in patients with resistant hypertension, changes in diastolic blood pressure, the proportion of participants achieving systolic blood pressure below 130 mmHg, and incidence of adverse events.
According to the statement, baxdrostat was generally well tolerated and exhibited a favorable safety profile. The company indicated that the data will be shared with regulatory authorities worldwide and are scheduled for presentation at the European Society of Cardiology Congress in August 2025.
Baxdrostat is described as a selective aldosterone synthase inhibitor, currently under investigation as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin for chronic kidney disease and prevention of heart failure in high-risk hypertensive patients.
AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. The company noted that a contingent value right of $10 per share, totaling $0.5 billion, is payable to former CinCor shareholders upon submission of a new drug application in the US or Europe.
This information is based on a press release statement included in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.